Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2023 | Novel insights from BTOG 2023

Tom Newsom-Davis • 3 May 2023
BTOG 2023
General Antibodies Checkpoint Inhibitors Pembrolizumab

Tom Newsom-Davis, BSc, MBBS, PhD, FRCP, Chelsea and Westminster Hospital, London, UK, shares his thoughts on some of the interesting presentations held at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 including one by NHS England’s Steve Williamson on the challenges faced by NHS England in implementing new drug regimens in the UK. This interview took place at BTOG 2023 in Belfast, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Tom Newsom-Davis

NSCLC with EGFR exon 20 insertions at WCLC 2026: PAPILLON & REZILIENT 3
3:41
NSCLC with EGFR exon 20 insertions at WCLC 2026: PAPILLON & REZILIENT 3
Tom Newsom-Davis • 14 Sep 2026
Ongoing lung cancer trials and the potential of Trop2 biomarker at BTOG 2025
0:54
Ongoing lung cancer trials and the potential of Trop2 biomarker at BTOG 2025
Tom Newsom-Davis • 3 Mar 2025
Challenges and future directions for antibody-drug conjugates (ADCs) in lung cancer therapy
2:09
Challenges and future directions for antibody-drug conjugates (ADCs) in lung cancer therapy
Tom Newsom-Davis • 3 Mar 2025
Targeting KRAS mutations in lung cancer
2:26
Targeting KRAS mutations in lung cancer
Tom Newsom-Davis • 18 Apr 2024

Related Videos

Cost-effectiveness of first-line chemo-immunotherapy in solid tumours
1:32
Cost-effectiveness of first-line chemo-immunotherapy in solid tumours
Jacopo Canzian • 23 Oct 2026
Pan-cancer TROP2 expression and survival in the MONSTAR-SCREEN-2 cohort
3:35
Pan-cancer TROP2 expression and survival in the MONSTAR-SCREEN-2 cohort
Kyosuke Seguchi • 23 Oct 2026
AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals